Joint position statement on management of patient with osteoporosis during COVID-19 contingency from the AMMOM, CONAMEGER, FELAEN, FEMECOG, FEMECOT, and ICAAFYD

• Published in: Archives of osteoporosis Vol. 16; no. 1; p. 18
• Main Authors: Torres-Naranjo, Francisco, De la Peña-Rodríguez, Pilar, López-Cervantes, Roberto Enrique, Morales-Torres, Jorge, Morales-Vargas, Jorge, Gutiérrez-Hermosillo, Hugo, Guzmán-Rico, Alan Christopher, González-Mendoza, Roberto Gabriel, Rueda Plata, Pedro Nel, Flores Castro, Miguel, Celis Gonzalez, Cuauhtémoc, Espinosa Morales, Rolando, Quintero Hernández, Sergio, López-Taylor, Juan Ricardo
• Format: Journal Article
• Language: English
• Published: London Springer London 25.01.2021
• Subjects: Aged; COVID-19; Endocrinology; Humans; Medicine; Medicine & Public Health; Orthopedics; Osteoporosis - epidemiology; Osteoporosis - therapy; Pandemics; Position Paper; SARS-CoV-2; Traumatology; COVID-19; Osteoporosis; SARS-CoV-2; Fragility fracture; Statement
• ISSN: 1862-3522; 1862-3514
• DOI: 10.1007/s11657-020-00869-3

Summary Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. This joint position statement of Latin American Medical Societies provides an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis. Background Infection by SARS-Cov-2 (COVID-19) has affected practically all the world. Characterized by high contagiousness, significative morbidity, and mortality in a segment of those infected, it has overwhelmed health services and forced to redirect resources to the emergency while impacting the attention of acute non-COVID-19 and many chronic conditions. Objective The objective of this study is to provide an updated guide for the prevention, diagnosis, and treatment of osteoporotic patients in the face of possible clinical scenarios posed by the COVID-19 health crisis. Methods A task force, of bone specialists with a wide range of disciplines in the field of osteoporosis and fragility fracture, was convened with the representation of several professional associations, namely, the Mexican Association of Bone and Mineral Metabolism (AMMOM), the National College of Geriatric Medicine (CONAMEGER), the Latin American Federation of Endocrinology (FELAEN), the Mexican Federation of Colleges of Obstetrics and Gynecology (FEMECOG), the Mexican Federation of Colleges of Orthopedics and Traumatology (FEMECOT), and the Institute of Applied Sciences for Physical Activity and Sports of the University of Guadalajara (ICAAFYD). Clinical evidence was collated, and an evidence report was rapidly generated and disseminated. After finding the gaps in the available evidence, a consensus opinion of experts was made. The resulting draft was reviewed and modified accordingly, in 4 rounds, by the participants. Results The task force approved the initial guidance statements, with moderate and high consensus. These were combined, resulting in the final guidance statements on the (1) evaluation of fracture risk; (2) stratification of risk priorities; (3) indications of bone density scans and lab tests; (4) initiation and continuation of pharmacologic therapy; (5) interruptions of therapy; (6) treatment of patients with incident fracture; (7) physical therapy and fall prevention; and (8) nutritional interventions. Conclusion These guidance statements are provided to promote optimal care to patients at risk for osteoporosis and fracture, during the current COVID-19 pandemic. However, given the low level of available evidence and the rapidly evolving literature, this guidance is presented as a “living document” and future updates are anticipated.